Back to results
US 2017/0320935 A1Published application
Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
OwnerJeffrey Ravetch, Falk Nimmerjahn +1inventors
InventorsJeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
Life of this patent
Estimating the term…
Abstract
The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
Claims11
-36. (canceled)
A method for preparing a pharmaceutical preparation comprising a recombinant IgG antibody having increased anti-inflammatory activity, the method comprising:
- expressing, in a host cell, a recombinant IgG antibody;
- subjecting the expressed recombinant IgG antibody to one or more purification steps to produce a preparation comprising the recombinant IgG antibody;
- treating the composition comprising the recombinant IgG antibody with an alpha-(2,6) sialylatransferase and a donor of sialic acid to increase the fraction of recombinant IgG antibody in the composition having alpha-2,6-linked N-acetylneuraminic acid on N-glycans of the Fc region of the recombinant IgG antibody thereby preparing a composition enriched for sialylated recombinant IgG antibody, wherein the enriched composition has increased anti-inflammatory activity relative to the un-enriched composition, and
- processing the composition enriched for sialylated recombinant IgG antibody to produce a pharmaceutical preparation, wherein the processing comprises combining the recombinant IgG antibody with a physiologically acceptable carrier, excipient or stabilizer, thereby preparing a pharmaceutical preparation comprising a recombinant IgG antibody having increased anti-inflammatory activity.
1 more element
Dependencies are inferred from the claim text.